Literature DB >> 20013333

[Medicinal therapy for interventional surgery of the peripheral vascular system].

J Tacke1, E Lindhoff-Last.   

Abstract

The aim of medicinal treatment, during and after femoral and crural interventions is to prevent early or late onset arterial thrombosis of the treated vascular segments. Therefore, unfractionated heparin is administered during the intervention by an intra-arterial or intravenous approach. To avoid late onset thrombosis, administration of platelet function inhibitors is recommended. However, valid data are only available for acetylsalicylic acid (ASA). Therefore, ASA is recommended for long term medication. In several cardiological studies on stent implantation in coronary vessels the combination of ASA and clopidogrel for dual platelet inhibition has been proven to be effective. These results have been transferred to antithrombotic therapy of the lower extremities despite the lack of dedicated studies. There is no evidence for the use of vitamin K antagonists after peripheral interventions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013333     DOI: 10.1007/s00117-009-1916-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  18 in total

1.  Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty.

Authors:  J Schweizer; A Müller; L Forkmann; G Hellner; W Kirch
Journal:  Angiology       Date:  2001-10       Impact factor: 3.619

2.  Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.

Authors:  Renate Koppensteiner; Silviana Spring; Béatrice R Amann-Vesti; Thomas Meier; Thomas Pfammatter; Valentin Rousson; Martin Banyai; Bernd van der Loo
Journal:  J Vasc Surg       Date:  2006-12       Impact factor: 4.268

Review 3.  The three processes leading to post PTCA restenosis: dependence on the lesion substrate.

Authors:  V Fuster; E Falk; J T Fallon; L Badimon; J H Chesebro; J J Badimon
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

4.  Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease.

Authors:  C Ranke; A Creutzig; G Luska; H H Wagner; M Galanski; S Bode-Böger; J Frölich; H J Avenarius; H Hecker; K ALexander
Journal:  Clin Investig       Date:  1994-09

5.  Balloon angioplasty and stent implantation induce a vascular inflammatory reaction.

Authors:  Martin Schillinger; Markus Exner; Wolfgang Mlekusch; Markus Haumer; Ramazanali Ahmadi; Helmut Rumpold; Oswald Wagner; Erich Minar
Journal:  J Endovasc Ther       Date:  2002-02       Impact factor: 3.487

6.  Platelet activation is increased in peripheral arterial disease.

Authors:  K Cassar; P Bachoo; I Ford; M Greaves; J Brittenden
Journal:  J Vasc Surg       Date:  2003-07       Impact factor: 4.268

7.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

8.  Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty.

Authors:  D D Do; F Mahler
Journal:  Radiology       Date:  1994-11       Impact factor: 11.105

9.  Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Michael Sobel; Raymond Verhaeghe
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results.

Authors:  E Pilger; J Lammer; H Bertuch; G Stark; M Decrinis; K P Pfeiffer; G J Krejs
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.